Topic: non-Hodgkin lymphoma
Emgality will likely chase Amgen and Novartis’ first-in-class Aimovig and Teva's Ajovy in the CGRP migraine field.
England's cost-effectiveness watchdogs gave Novartis the go-ahead for its CAR-T drug, Kymriah, to treat leukemia.
Lenvima's quarterly sales grow to $106 million; China makes 48-drug list for streamlined review; Samsung commits further investment in biologics.
Kyowa is also testing the drug in early-phase trials for solid tumors, in combo with its own IDO inhibitor KHK2455, BMS’ Opdivo and AZ’s Imfinzi.
Celgene ended a losing streak Monday with a Revlimid trial win, and one analyst thinks more rosy pipeline events could follow soon.
J&J and AbbVie’s Imbruvica hasn’t run into many stumbling blocks. But it has hit one in non-Hodgkin lymphoma.
Imbruvica is the only treatment for Waldenström's macroglobulinemia patients. But before competition hits, its makers are pushing for a wider market.
Another day, another approval for Merck immuno-oncology star Keytruda.
If the competition between Novartis and Gilead in relapsed large B-cell lymphoma comes down to price, it will be a close race.
Merck’s quest to move Keytruda further into blood cancers hit a snag over the summer, but now, it’s back on track.